Clinical Trial Update: Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating a radioactive tracer plus ultrasound detector for imaging prostate cancer, compared with MRI and the ProstaScint radiotracer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ProstaScint (capromab pendetide)

Snippet

Sponsor: Radiological Associates of Sacramento Medical Group Inc. | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: UNKNOWN